Switch theme
Sign up to access all valuation multiples
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
2011
265
LTM Revenue $73.6M
Last FY EBITDA -$103M
$235M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ADC Therapeutics has a last 12-month revenue (LTM) of $73.6M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, ADC Therapeutics achieved revenue of $70.8M and an EBITDA of -$103M.
ADC Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ADC Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $73.6M | XXX | $70.8M | XXX | XXX | XXX |
| Gross Profit | $67.0M | XXX | $64.9M | XXX | XXX | XXX |
| Gross Margin | 91% | XXX | 92% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$103M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -145% | XXX | XXX | XXX |
| EBIT | -$135M | XXX | -$130M | XXX | XXX | XXX |
| EBIT Margin | -184% | XXX | -183% | XXX | XXX | XXX |
| Net Profit | -$165M | XXX | -$158M | XXX | XXX | XXX |
| Net Margin | -224% | XXX | -223% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, ADC Therapeutics's stock price is $3.
ADC Therapeutics has current market cap of $306M, and EV of $235M.
See ADC Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $235M | $306M | XXX | XXX | XXX | XXX | $-1.61 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, ADC Therapeutics has market cap of $306M and EV of $235M.
ADC Therapeutics's trades at 3.3x EV/Revenue multiple, and -2.3x EV/EBITDA.
Equity research analysts estimate ADC Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ADC Therapeutics has a P/E ratio of -1.9x.
See valuation multiples for ADC Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $306M | XXX | $306M | XXX | XXX | XXX |
| EV (current) | $235M | XXX | $235M | XXX | XXX | XXX |
| EV/Revenue | 3.2x | XXX | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -2.3x | XXX | XXX | XXX |
| EV/EBIT | -1.7x | XXX | -1.8x | XXX | XXX | XXX |
| EV/Gross Profit | 3.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.9x | XXX | -1.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialADC Therapeutics's last 12 month revenue growth is 11%
ADC Therapeutics's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.7M for the same period.
ADC Therapeutics's rule of 40 is -198% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ADC Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ADC Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -145% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -198% | XXX | -134% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 30% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 155% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 275% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ADC Therapeutics acquired XXX companies to date.
Last acquisition by ADC Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . ADC Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was ADC Therapeutics founded? | ADC Therapeutics was founded in 2011. |
| Where is ADC Therapeutics headquartered? | ADC Therapeutics is headquartered in United States of America. |
| How many employees does ADC Therapeutics have? | As of today, ADC Therapeutics has 265 employees. |
| Who is the CEO of ADC Therapeutics? | ADC Therapeutics's CEO is Mr. Ameet Mallik. |
| Is ADC Therapeutics publicy listed? | Yes, ADC Therapeutics is a public company listed on NYS. |
| What is the stock symbol of ADC Therapeutics? | ADC Therapeutics trades under ADCT ticker. |
| When did ADC Therapeutics go public? | ADC Therapeutics went public in 2020. |
| Who are competitors of ADC Therapeutics? | Similar companies to ADC Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of ADC Therapeutics? | ADC Therapeutics's current market cap is $306M |
| What is the current revenue of ADC Therapeutics? | ADC Therapeutics's last 12 months revenue is $73.6M. |
| What is the current revenue growth of ADC Therapeutics? | ADC Therapeutics revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of ADC Therapeutics? | Current revenue multiple of ADC Therapeutics is 3.2x. |
| Is ADC Therapeutics profitable? | Yes, ADC Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
